Lawrence Blatt, MBA., Ph.D., co-founded Aligos Therapeutics, Inc., and currently serves as the Chief Executive Officer and a member of the Board of Directors since March 2018. Dr. Blatt has more than 29 years of drug research and development experience with a specific focus on biology of the immune system, infectious diseases, antiviral therapies, and relevant therapeutic interventions. Prior to Aligos, he was the Global Head of Infectious Diseases and Vaccines at Johnson & Johnson.
A serial biotech entrepreneur, Dr. Blatt co-founded Alios BioPharma, Inc., and served as its Chief Executive Officer, President and Director from inception to acquisition by Johnson & Johnson in 2014, overseeing the development of therapies for viral diseases, including respiratory syncytial virus (RSV) and hepatitis C. Prior to Alios, he was Chief Scientific Officer of InterMune, Inc. (acquired by Roche in 2014). Dr. Blatt also held successive positions as Vice President of Research of SiRNA/Ribozyme Therapeutics, Vice President of Product Development at National Genetics Institute, and Product Development Team Leader, Interferons at Amgen.
Dr. Blatt received a Doctorate in public health administration from the University of La Verne and completed his MBA from California State University, Northridge and Bachelor of Science degree in Microbiology from Indiana University. He is also a co-founder and chairman of the Board of Directors for Alveo Technologies, Inc.
Dr. Blatt was the recipient of the Ernst & Young Entrepreneur of the Year Award (2012) in the life science category and has co-authored over 100 peer-reviewed scientific publications. He is also listed as a co-inventor on several issued and pending patent applications relating to treatment of viral diseases.